Lung Cancer Market Know About Growth Rate, Trends, Segmentation and Key Players | MRFR

 

Lung Cancer Market Overview

The Lung Cancer Market is estimated to record a CAGR of 9.11% and is slated to reach USD 30.5 billion by the end of the forecast period by 2030. 

Market Dynamics

The rise in long-term cigarette smoking is to blame for the rise in lung cancer cases, which now account for nearly 85 percent of all cancer cases worldwide. The rise in environmental pollution is a serious issue that necessitates more policies to combat it. High levels of ozone, on the other hand, have been related to a higher rate of cancer detection in people who have been exposed to it for a longer period. The diagnosis of cancer cases has improved, making lung cancer therapies such as chemotherapy and surgery more accessible than before, improving the lung cancer care market share during the forecast period. Several insurance companies are expected to expand to provide cancer-related treatment and care over the forecast period, boosting the lung cancer therapeutics industry.

The increased amount of research being directed at various cancer types, including lung cancer, is expected to open new growth areas for the global market. The help of private foundations and organizations in terms of funding for lung cancer therapeutics market research and patient care, as well as additional research into its treatment and diagnosis, is expected to boost the lung cancer market size during the forecast period.

Treatments for lung cancer and other cancers must be licensed by regulatory bodies with high standards and stringent testing procedures, which could limit market development. In the forecast period, the decreased life expectancy of patients undergoing lung cancer care due to the lack of lung organ transplants is expected to reduce growth potential.

Because of the COVID-19 pandemic, there have been a slew of significant delays in the process of identification, diagnosis, and treatment, which have been repeatedly found across all types of cancer in the United Kingdom. Pre-COVID, cancer was steadily identified as the leading cause of death worldwide, and lung cancer kills approximately 35 000 people per year, which is more than breast and bowel cancers combined. Experts expect an additional 1372 lung cancer deaths five years after the discovery of COVID-19 due to a significant rise in lung cancer's late-stage presence. COVID-19 is more acute in lung cancer patients because the determinants are more patient-specific, such as smoking status and chronic obstructive pulmonary disease (COPD), rather than tumor-specific characteristics or therapies.

Regional Overview

North America's lung cancer market will be the highest, but its share will be declining. The supremacy of North America is due to its excellent healthcare system and rising per capita disposable incomes. The health-care systems in North American countries such as the United States (US) and Canada are integrated and well-structured. In addition, these programs promote research and development. These policies allow international companies to invest in the United States and Canada. As a result, these countries have many global market participants. The market is expected to grow further as high demand is met by the presence of global players in the region.

The European regional market will be the global market's second most important market. Turkey, Denmark, Hungary, Belarus, Poland, Armenia, and Belgium are leading the European region in lung cancer detection.

Due to a large population base of smokers, the Asia Pacific region is expected to be the fastest maturing market for lung cancer therapeutics. Furthermore, due to increased awareness, some small players are emerging in Asia-Pacific. This has also aided the market's expansion. This enormous growth is anticipated because of the awareness about improved health care and the existence of unmet medical needs for cancer therapeutics in India and China, which are still untapped markets. Due to the rise in the number of smokers and people affected by lung cancer, the emerging economies of India and China would produce most of the revenue in Asia Pacific. China, South Korea, Japan, and Kazakhstan's national markets are expected to be at the forefront of this growth. Furthermore, in 2016, the Australian national market had a market share of 10.3 percent.

Competitive Dynamics

The Lung Cancer Market players are Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Pfizer (U.S.), Merck & Co., Inc. (U.S.), Bristol-Myers Squibb (U.S.), Eli Lilly and Company (U.S.), and Sanofi (France), among others.

Market segmentation

By Type, the NSCLC type segment is estimated to lead the type-based segment in the forecast period.

By Treatment, the surgery and chemotherapy segments are estimated to control the treatment-based segment's majority stake in the forecast period.

By End-User, the hospitals & clinics segment is forecasted to control a massive share in the end- user segment through the forecast period.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com

Comments

Post a Comment

Popular posts from this blog

Cardiac Monitoring and Cardiac Rhythm Management Device Market Growth Opportunities, Demand and Forecasts, 2020-2027

  Market Highlights The increasing demand for minimally invasive surgeries drives the growth of this market. Advanced technologies in cardiac monitoring and cardiac rhythm management devices have also led to growth in this market.  However, factors such as stringent regulatory approval procedures, the high cost of cardiac devices, and lack of reimbursement policies in developing countries are hindering the growth of the market. Rising prevalence of cardiovascular diseases and the increasing number of unmet medical needs in undeveloped countries are leading to the growth of the  cardiac monitoring and cardiac rhythm management device market . Technical advancements in drug-eluting, MRI compatible pacemakers, and Holter monitors are some of the factors leading to the growth of this market. The growth of the global cardiac monitoring device market is driven by the high prevalence of cardiovascular disorders worldwide. Segmentation The global cardiac monitoring and  card...
Read more

Cancer Biological Therapy Market Demand, Business Strategies, Current Trends And Efficient Techniques, Forecast 2030

  Market Highlights Cancer is the leading and second largest cause of death across the globe. The disease is characterized by disordered and deregulated cellular and stromal explosion along with reduced cell death and growth factor deprivation, and such other factors. These various types of biological therapies, which are most of the times stated to biological modifier therapy or immunotherapy, but these types of therapies do not always target cancer cells directly. Further there are other biological therapies like sections of genetic material or antibodies which are commonly known as DNA or RNA, do aim at targeting cancer cells directly. There are also other types of biological therapies that inhibit specific molecules involved in development and growth of cancer tumor. Such therapies known as; cancer targeted therapies. Cancer Biological therapy market  treatment is done with the help of living organisms, parts of living organisms or laboratory manufactured version of such c...
Read more

Medical Imaging Software Market SWOT Analysis, Dynamics, Drivers, Key Indicators and Forecast to 2022-2030

  Medical Imaging Software Market Highlights Medical imaging software supports processing and producing high-resolution images of the internal body parts of a human for disease diagnosis and treatment. The emergence of 3D and 4D imaging technologies, increasing the prevalence of geriatric population and subsequent growth in the incidence of cardiac, and neurological diseases including cancer, growing government funding’s for development of medical diagnostics field are some factors that are anticipated to drive the market growth during the assessment period.  Additionally, a rise in the number of diagnostic centres and increased healthcare expenditure is likely to contribute to market growth. As per the data by the Office for National Statistics, in 2016, the gross domestic expenditure on research and development (R&D) was Euro 33.1 billion (USD 35.2 billion) in the UK. However, the high cost of equipment related to clinical validation and lack of skilled professionals m...
Read more